Edition:
United States

Fennec Pharmaceuticals Inc (FENC.OQ)

FENC.OQ on NASDAQ Stock Exchange Capital Market

9.15USD
15 Dec 2017
Change (% chg)

$0.10 (+1.10%)
Prev Close
$9.05
Open
$9.14
Day's High
$9.15
Day's Low
$9.07
Volume
6,950
Avg. Vol
--
52-wk High
$13.96
52-wk Low
$8.23

Chart for

About

Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the... (more)
No analyst recommendations are available for .

Overall

Beta: -0.28
Market Cap(Mil.): $186.73
Shares Outstanding(Mil.): 15.87
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Fennec Announces Pricing Of Public Offering

* SAYS PUBLIC OFFERING OF 2.35 MILLION COMMON SHARES PRICED AT $8.50PER SHARE Source text for Eikon: Further company coverage:

Dec 08 2017

BRIEF-Fennec Pharmaceuticals Q3 loss per share $0.15‍​

* Fennec provides business update and reports third quarter 2017 results

Nov 13 2017

BRIEF-Fennec pharmaceuticals files for stock shelf of up to $90 mln

* Files for stock shelf of up to $90 million - SEC filing‍​ Source text (http://bit.ly/2h66FIr) Further company coverage:

Oct 24 2017

BRIEF-Fennec announces positive results from phase 3 SIOPEL 6 study on Pedmark

* Fennec announces positive results from phase 3 SIOPEL 6 study on Pedmark (sodium thiosulfate) presented at the 49th Congress of the international Society of Pediatric Oncology (SIOP) 2017 meeting

Oct 16 2017

BRIEF-Fennec announces preliminary results of SIOPEL 6 study on PEDMARK to be presented at SIOP meeting

* Fennec announces preliminary results of SIOPEL 6 study on PEDMARK(sodium thiosulfate) to be presented at the 49th Congress of the International Society Of Pediatric Oncology (SIOP) 2017 meeting

Sep 13 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $142.46 +0.81
Roche Holding Ltd. (ROG.S) CHF244.10 +2.40
Roche Holding Ltd. (RO.S) CHF243.40 +0.90
Pfizer Inc. (PFE.N) $37.20 +0.74
Novartis AG (NOVN.S) CHF83.80 -0.05
Sanofi SA (SASY.PA) €73.55 -0.22
Abbott Laboratories (ABT.N) $55.50 +0.77
Merck & Co., Inc. (MRK.N) $56.24 +0.23
AstraZeneca plc (AZN.L) 4,881.00 -3.50
Amgen, Inc. (AMGN.OQ) $177.04 +2.12

Earnings vs. Estimates

No consensus analysis data available.